J
Johannes Schmid
Researcher at Aarhus University Hospital
Publications - 44
Citations - 1119
Johannes Schmid is an academic researcher from Aarhus University Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 10, co-authored 27 publications receiving 763 citations. Previous affiliations of Johannes Schmid include Odense University Hospital & Aarhus University.
Papers
More filters
Journal ArticleDOI
EAACI Molecular Allergology User's Guide.
Paolo Maria Matricardi,Jörg Kleine-Tebbe,Hans Jürgen Hoffmann,Rudolf Valenta,Christiane Hilger,Stephanie Hofmaier,Rob C. Aalberse,Ioana Agache,Riccardo Asero,Barbara Ballmer-Weber,Domingo Barber,Kirsten Beyer,Tilo Biedermann,M. B. Bilò,Simon Blank,Barbara Bohle,Philipp P. Bosshard,Heimo Breiteneder,Helen A. Brough,Luis Caraballo,J-C Caubet,Reto Crameri,Janet M. Davies,Nikolaos Douladiris,M. Ebisawa,Philippe Eigenmann,Montserrat Fernandez-Rivas,Fatima Ferreira,Gabriele Gadermaier,Martin Glatz,Robert G. Hamilton,Thomas Hawranek,P W Hellings,Karin Hoffmann-Sommergruber,Thilo Jakob,Uta Jappe,Marek Jutel,Sandip D. Kamath,Edward F. Knol,Peter Korošec,Annette Kuehn,Gideon Lack,Gideon Lack,Andreas L. Lopata,Mika J. Mäkelä,Martine Morisset,Verena Niederberger,Anna Nowak-Wegrzyn,Nikolaos G. Papadopoulos,Elide A. Pastorello,Gabrielle Pauli,Thomas A.E. Platts-Mills,Daniela Posa,Lars K. Poulsen,Monika Raulf,Joaquín Sastre,Enrico Scala,Johannes Schmid,Peter Schmid-Grendelmeier,M. van Hage,R. van Ree,Stefan Vieths,Richard W. Weber,Magnus Wickman,Antonella Muraro,Markus Ollert +65 more
TL;DR: The European Academy of Allergy and Clinical Immunology (EAACI) Molecular Allergology User's Guide (MAUG) as mentioned in this paper provides comprehensive information on important allergens and describes the diagnostic options using component-resolved diagnosis (CRD).
Journal ArticleDOI
Novel approaches and perspectives in allergen immunotherapy
Hans Jürgen Hoffmann,Hans Jürgen Hoffmann,Erkka Valovirta,Oliver Pfaar,P. Moingeon,Johannes Schmid,Johannes Schmid,Søren Helbo Skaarup,Søren Helbo Skaarup,Lars-Olaf Cardell,Lars-Olaf Cardell,K. Simonsen,Mark Larché,Stephen R. Durham,P. Sørensen +14 more
TL;DR: Novel treatments such as peptide immunotherapy, intralymphatic immunotherapy and use of recombinant allergens herald a new age in which AIT may address treatment of allergy as a public health issue by reaching a large fraction of patients.
Journal ArticleDOI
Intralymphatic Immunotherapy: Update and Unmet Needs.
Gabriela Senti,Andreas U. Freiburghaus,Désirée Larenas-Linnemann,Hans Jürgen Hoffmann,Hans Jürgen Hoffmann,Amber M. Patterson,Ludger Klimek,Danilo Di Bona,Oliver Pfaar,Lars Ahlbeck,Mübeccel Akdis,Dan Weinfeld,Francisco A. Contreras-Verduzco,Alvaro Pedroza-Melendez,Søren Helbo Skaarup,Sang Min Lee,Lars-Olaf Cardell,Johannes Schmid,Ulla Westin,Ralph Dollner,Thomas M. Kündig +20 more
TL;DR: The clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.
Journal ArticleDOI
Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract
TL;DR: Pretreatment allergen component-specific IgE appears to determine the induction of IgG4 in the updosing phase of subcutaneous immunotherapy, resulting in a marked decrease in ISAC-measured specific IgE levels after updosing of SCIT, which can be used to monitor the blocking effect ofallergen-specific immunotherapy-induced non-IgE antibodies.